Undervalued Opportunities: Penny Stocks To Watch In September 2026

The United States market remained flat over the last week but has risen by 12% over the past year, with earnings forecasted to grow annually by 17%. For investors seeking opportunities in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value. These stocks, when backed by solid financials, may provide a mix of affordability and growth potential; we explore several that stand out for their financial strength.

We're going to check out a few of the best picks from our screener tool.

Vuzix (VUZI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Vuzix Corporation designs, manufactures, and markets AI-powered smart glasses, waveguides, and augmented reality technologies globally with a market cap of $216.94 million.

Operations: The company's revenue is derived from its video eyewear products, totaling $5.91 million.

Market Cap: $216.94M

Vuzix Corporation, with a market cap of US$216.94 million, is navigating the challenges typical for companies in the penny stock category. Despite being unprofitable and experiencing increased losses over five years, Vuzix has no debt and maintains strong short-term asset coverage over liabilities. The company recently raised US$100 million through a follow-on equity offering to bolster its cash runway beyond the current 8 months based on free cash flow estimates. Recent product advancements include shipping Causeway waveguide bridge samples aimed at enhancing optical interconnect applications, signaling potential revenue growth opportunities despite its recent index drops.

• Navigate through the intricacies of Vuzix with our comprehensive balance sheet health report here.
• Learn about Vuzix's future growth trajectory here.

Cerus (CERS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cerus Corporation is a biomedical products company with a market cap of approximately $509.86 million.

Operations: The company's revenue is generated from its Blood Safety segment, amounting to $221.55 million.

Market Cap: $509.86M

Cerus Corporation, with a market cap of US$509.86 million, operates within the biomedical sector and continues to navigate challenges inherent to penny stocks. Despite being unprofitable with a negative return on equity of -9.66%, Cerus has demonstrated resilience by reducing losses at an annual rate of 30.8% over five years and maintaining a satisfactory net debt-to-equity ratio of 12.2%. The company has sufficient cash runway for over three years, supported by stable free cash flow growth rates. Recent guidance revisions project full-year 2026 revenue between US$229 million and US$231 million, indicating steady growth prospects amidst ongoing financial adjustments including recent shelf registration filings for $28.7 million in common stock offerings.

• Take a closer look at Cerus' potential here in our financial health report.
• Assess Cerus' future earnings estimates with our detailed growth reports.

NIO (NIO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: NIO Inc. designs, develops, manufactures, and sells smart electric vehicles in China, Europe, and internationally with a market cap of approximately $8.96 billion.

Operations: NIO's revenue primarily comes from its smart electric vehicles related business, totaling CN¥114.11 billion.

Market Cap: $8.96B

NIO Inc., with a market cap of approximately $8.96 billion, is navigating the challenges typical of penny stocks while expanding its presence in the smart electric vehicle sector. Despite being unprofitable and having a negative return on equity of -33.17%, NIO has shown significant revenue growth, reporting CN¥32.14 billion for Q2 2026 compared to CN¥19 billion a year ago, and reducing quarterly net losses from CN¥5.14 billion to CN¥721 million year-over-year. The company maintains stable weekly volatility at 5% and projects substantial vehicle delivery growth with expected revenues between US$4.91 billion and US$5.02 billion for Q3 2026, signaling potential for continued expansion despite financial hurdles.

• Get an in-depth perspective on NIO's performance by reading our balance sheet health report here.
• Understand NIO's earnings outlook by examining our growth report.

Taking Advantage

• Unlock more gems! Our US Penny Stocks screener has unearthed 315 more companies for you to explore.Click here to unveil our expertly curated list of 318 US Penny Stocks.
• Ready For A Different Approach? This technology could replace computers: discover the 25 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com